OBJECTIVE: To report our long-term follow-up of an institutional randomized prospective trial of radical prostatectomy (RP) with or without a 3-month course of neoadjuvant hormone therapy (NHT), which results in pathological downstaging, but generally no reduction in biochemical recurrence (BCR) on early follow-up (at 3 years). PATIENTS AND METHODS: From December 1992 to June 1996, 148 patients with clinically localized prostate cancer were randomized to RP only or 3 months of goserelin acetate and flutamide before RP. BCR was defined as a detectable serum prostate specific antigen level (>0.1 ng/mL) at least 6 weeks after surgery, with a confirmatory increase. RESULTS: The median follow-up for BCR-free patients was 8 years. There was no significant difference in BCR-free probabilities between groups (P = 0.7). The BCR-free probability at 7 years was 78% for patients undergoing RP only and 80% for patients undergoing NHT and RP (difference of 2%; 95% confidence interval, CI, 12-16%). A Cox regression showed no significant relationship between NHT and BCR (hazard ratio 1.16; 95% CI, 0.56-2.39, P = 0.7). Overall, two patients had local recurrence and six developed metastases, and were evenly distributed among the RP only and NHT groups. CONCLUSION: Although our study was not originally powered to detect differences in BCR, there was no overall benefit in BCR-free probability, local recurrence or metastasis with 3 months of NHT at 8 years of follow-up. Pending evidence of improvement in patient outcomes, NHT before RP appears to be unjustified outside of clinical trials.
RCT Entities:
OBJECTIVE: To report our long-term follow-up of an institutional randomized prospective trial of radical prostatectomy (RP) with or without a 3-month course of neoadjuvant hormone therapy (NHT), which results in pathological downstaging, but generally no reduction in biochemical recurrence (BCR) on early follow-up (at 3 years). PATIENTS AND METHODS: From December 1992 to June 1996, 148 patients with clinically localized prostate cancer were randomized to RP only or 3 months of goserelin acetate and flutamide before RP. BCR was defined as a detectable serum prostate specific antigen level (>0.1 ng/mL) at least 6 weeks after surgery, with a confirmatory increase. RESULTS: The median follow-up for BCR-free patients was 8 years. There was no significant difference in BCR-free probabilities between groups (P = 0.7). The BCR-free probability at 7 years was 78% for patients undergoing RP only and 80% for patients undergoing NHT and RP (difference of 2%; 95% confidence interval, CI, 12-16%). A Cox regression showed no significant relationship between NHT and BCR (hazard ratio 1.16; 95% CI, 0.56-2.39, P = 0.7). Overall, two patients had local recurrence and six developed metastases, and were evenly distributed among the RP only and NHT groups. CONCLUSION: Although our study was not originally powered to detect differences in BCR, there was no overall benefit in BCR-free probability, local recurrence or metastasis with 3 months of NHT at 8 years of follow-up. Pending evidence of improvement in patient outcomes, NHT before RP appears to be unjustified outside of clinical trials.
Authors: M E Gleave; S L Goldenberg; J L Chin; J Warner; F Saad; L H Klotz; M Jewett; V Kassabian; M Chetner; C Dupont; S Van Rensselaer Journal: J Urol Date: 2001-08 Impact factor: 7.450
Authors: S L Goldenberg; L H Klotz; J Srigley; M A Jewett; D Mador; Y Fradet; J Barkin; J Chin; J M Paquin; M J Bullock; S Laplante Journal: J Urol Date: 1996-09 Impact factor: 7.450
Authors: Peter Swindle; James A Eastham; Makoto Ohori; Michael W Kattan; Thomas Wheeler; Norio Maru; Kevin Slawin; Peter T Scardino Journal: J Urol Date: 2008-05 Impact factor: 7.450
Authors: Tianzhu Zang; Mary-Ellen Taplin; Daniel Tamae; Wanling Xie; Clementina Mesaros; Zhenwei Zhang; Glenn Bubley; Bruce Montgomery; Steven P Balk; Elahe A Mostaghel; Ian A Blair; Trevor M Penning Journal: Endocr Relat Cancer Date: 2017-06-29 Impact factor: 5.678
Authors: John Thoms; Jayant S Goda; Alexender R Zlotta; Neil E Fleshner; Theodorus H van der Kwast; Stéphane Supiot; Padraig Warde; Robert G Bristow Journal: Nat Rev Clin Oncol Date: 2010-12-21 Impact factor: 66.675
Authors: William T Lowrance; Elena B Elkin; David S Yee; Andrew Feifer; Behfar Ehdaie; Lindsay M Jacks; Coral L Atoria; Michael J Zelefsky; Howard I Scher; Peter T Scardino; James A Eastham Journal: BJU Int Date: 2011-11-15 Impact factor: 5.588
Authors: Rana R McKay; Bruce Montgomery; Wanling Xie; Zhenwei Zhang; Glenn J Bubley; David W Lin; Mark A Preston; Quoc-Dien Trinh; Peter Chang; Andrew A Wagner; Elahe A Mostaghel; Philip W Kantoff; Peter S Nelson; Adam S Kibel; Mary-Ellen Taplin Journal: Prostate Cancer Prostatic Dis Date: 2017-12-20 Impact factor: 5.554
Authors: Jonathan L Silberstein; Stephen A Poon; Daniel D Sjoberg; Alexandra C Maschino; Andrew J Vickers; Aaron Bernie; Badrinath R Konety; W Kevin Kelly; James A Eastham Journal: BJU Int Date: 2015-04-17 Impact factor: 5.588